MedTrace Logo

Testosterone Therapy in Heart Failure

NCT01377103 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-07-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether benefits of topical testosterone on symptoms and function of male HF patients, and its effects on rehospitalization rates and quality of life.

Conditions

Interventions

DRUG

testerone gel

5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel

DRUG

Placebo

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Ernst Schwarz, MD, PhD · Cedars-Sinai Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
36 Years
Max Age
79 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-10-31
Completion
2012-12-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01377103 on ClinicalTrials.gov